{"id":"las41005","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP levels in immune and inflammatory cells. This suppresses the production of pro-inflammatory cytokines and chemokines, reducing inflammation. The mechanism is designed to provide anti-inflammatory effects with potentially improved tolerability compared to earlier PDE4 inhibitors.","oneSentence":"LAS41005 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:17.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT00987246","phase":"PHASE3","title":"Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2008-06","conditions":"Actinic Keratosis","enrollment":470},{"nctId":"NCT01358851","phase":"PHASE2","title":"LAS41005 in Hyperkeratotic Actinic Keratosis","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2011-04","conditions":"Actinic Keratosis","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LAS41005","genericName":"LAS41005","companyName":"Almirall, S.A.","companyId":"almirall-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LAS41005 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}